CVAC230120P00092500
- Reuters
BioNTech, Pfizer sue CureVac in U.S. over COVID-19 vaccine patent claims
COVID-19 vaccine maker BioNTech said on Tuesday that it and partner Pfizer have filed a complaint with the U.S. District Court in Massachusetts, seeking a judgment that they did not infringe U.S. patents held by rival CureVac. The lawsuit, filed Monday, said CureVac is trying to profit from the success of BioNTech and Pfizer's COVID-19 vaccines after CureVac's efforts to create its own vaccine failed.
- Zacks
Wall Street Analysts Predict a 96% Upside in CureVac N.V. (CVAC): Here's What You Should Know
The mean of analysts' price targets for CureVac N.V. (CVAC) points to a 96.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
- Simply Wall St.
Analysts Expect Breakeven For CureVac N.V. (NASDAQ:CVAC) Before Long
We feel now is a pretty good time to analyse CureVac N.V.'s ( NASDAQ:CVAC ) business as it appears the company may be...
